Palisade Bio (PALI) Profit After Tax Growth (3y) (2013 - 2026)

Palisade Bio (PALI) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Palisade Bio 424.57 Mn 291.94 Mn - -60.09%

Historic Data

Download Data
DateValue
Mar 31, 2026 -60.09%
Dec 31, 2025 -33.74%
Sep 30, 2025 10.43%
Jun 30, 2025 -5.90%
Mar 31, 2025 19.06%
Dec 31, 2024 -72.32%
Sep 30, 2024 -34.46%
Jun 30, 2024 49.53%
Mar 31, 2024 4.35%
Dec 31, 2023 11.21%
Sep 30, 2023 -24.96%
Jun 30, 2023 -22.38%
Mar 31, 2023 0.62%
Dec 31, 2022 -22.22%
Sep 30, 2022 -31.19%
Jun 30, 2022 -17.72%
Mar 31, 2022 -10.53%
Dec 31, 2021 74.90%
Sep 30, 2021 85.83%
Jun 30, 2021 -269.94%